相关实验视频
Updated: Jun 22, 2025
06:08
Transcranial Pulse Stimulation for Alzheimer's Patients
Published on: April 4, 2025
522
时间编码的ASL揭示了早期AD连续的下脑血流
Carles Falcon1,2,3, Paula Montesinos4, Lena Václavů5
1Barcelonaβeta Brain Research Center (BBRC), Pasqual Maragall Foundation, Barcelona, Spain.
概括
大脑血流 (CBF) 减少是阿尔茨海默病 (AD) 的早期迹象. 时间编码ASL (te-ASL) 在检测这些早期CBF变化方面比单个PLDASL更敏感.
科学领域:
- 神经成像是一种神经成像.
- 阿尔茨海默氏症疾病研究研究
- 脑血管健康 脑血管健康
背景情况:
- 阿尔茨海默病 (AD) 的认知障碍与大脑血流 (CBF) 的减少有关.
- 早期发现AD生物标志物和相关的生理变化对于了解疾病进展至关重要.
研究的目的:
- 评估时间编码的动脉旋转标记 (te-ASL) 在检测AD连续性的CBF变化时的灵敏度.
- 研究CBF和AD生物标志物,神经退行和认知功能在认知不受损 (CU) 个体之间的关联.
主要方法:
- 一项研究将te-ASL与单次后标签延迟 (PLD) ASL进行比较,用于测量AD连续的59名成年人的CBF (CU粉样蛋白β (Aβ) 阴性,CU Aβ阳性和CI Aβ+).
- 在CU参与者中探索CBF与AD病理,脑血管疾病,突触功能障碍和神经退行症的生物标志物之间的相关性.
主要成果:
- te-ASL在确定CBF减少方面表现出更高的灵敏度,无论是具有阳性粉样蛋白生物标志物的CU个体,还是具有阳性粉样蛋白生物标志物的认知障碍 (CI) 个体.
- 在CU参与者中,降低CBF与与粉样蛋白,蛋白,突触功能障碍和神经退行相关的生物标志物发生变化显著相关.
结论:
- 大脑血流减少是一个早期的指标,即使在AD连续体内的认知不受损的个体中也可以检测到.
- te-ASL是一种比单PLD ASL更敏感的成像技术,用于检测AD的背景下CBF变化.
- CBF与关键的AD生物标志物,突触健康和神经退行过程密切相关.
关键词:
阿尔茨海默病的疾病阿尔茨海默病的疾病.氨基βββββββββββββββββββββββββ磁共振成像技术的使用神经退行症的神经退行症神经纤维光的光源是神经纤维光.在p-tau.一个单一的后标签延迟动脉旋转标签.突触功能障碍 突触功能障碍蛋白质是一种蛋白质.更多相关视频
06:23The 4 Mountains Test: A Short Test of Spatial Memory with High Sensitivity for the Diagnosis of Pre-dementia Alzheimer's Disease
Published on: October 13, 2016
32.3K
11:01Examining the Characteristics of Episodic Memory using Event-related Potentials in Patients with Alzheimer's Disease
Published on: August 30, 2011
13.6K
相关概念视频
01:26Alzheimer's Disease: Overview
461
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
461
01:22Alzheimer's Disease: Treatment
177
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
177
01:30Dementia
110
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
The progression of dementia is generally gradual....
110